Aerovance, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.aerovance.com
Clinical Trials
10
Active:5
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
3 (42.9%)A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- Aerovance, Inc.
- Target Recruit Count
- 424
- Registration Number
- NCT00801853
- Locations
- 🇺🇸
Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
🇺🇸Allergy and Immunology Associates Ltd, Scottsdale, Arizona, United States
🇺🇸Allergy and Asthma Specialists Medical Group, Huntington Beach, California, United States
A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects
Phase 1
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Aerovance, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00785668
- Locations
- 🇬🇧
Guy's Drug Research Unit a division of Quintiles Ltd., London, England, United Kingdom
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
Phase 2
Completed
- Conditions
- Atopic Eczema
- Interventions
- Drug: placeboDrug: Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2008-05-13
- Lead Sponsor
- Aerovance, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00676884
- Locations
- 🇬🇧
Guy's Drug Research unit, Quintiles Limited, London, United Kingdom
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Aerovance, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00535431
- Locations
- 🇬🇧
Guy's Drug Research Unit, Quintiles, Ltd., London, United Kingdom
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Aerovance, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00535028
- Locations
- 🇬🇧
Guy's Drug Research Unit, Quintiles, Ltd., 6 Newcomen Street London, London, United Kingdom
News
No news found